Neurological medications: nursing reference guide

Neurological pharmacology is consistently high-yield on NCLEX and challenging in clinical practice. Nurses managing patients with epilepsy, Parkinson’s disease, multiple sclerosis, or Alzheimer’s dementia must understand drug mechanisms well enough to catch toxicity early, time doses precisely, and teach patients what to watch for at home. The stakes are high: phenytoin toxicity can cause cardiac arrest, abrupt levodopa discontinuation can trigger a life-threatening dopaminergic crisis, and a missed PML warning sign in a natalizumab patient can be fatal.

This reference covers four major neurological drug categories — anti-epileptic drugs (AEDs), anti-Parkinson’s medications, MS disease-modifying therapies, and Alzheimer’s and dementia medications — with NCLEX-focused nursing implications for each. Use it alongside the seizure nursing reference, the Parkinson’s disease nursing guide, the Alzheimer’s disease nursing guide, and the multiple sclerosis nursing reference.

Quick reference: neurological drug class overview

Anti-epileptic drugs (AEDs)

Anti-epileptic drugs suppress or prevent seizure activity through a range of mechanisms — most commonly by blocking voltage-gated sodium channels (stabilizing neuron membranes), enhancing GABA-mediated inhibition, or reducing glutamate-mediated excitation. No single AED is first-line for all seizure types; drug selection depends on seizure classification, patient age, sex, comorbidities, and tolerance profile. For a complete overview of seizure classification and the status epilepticus protocol, see the seizure nursing reference.

NCLEX tests nursing management of AEDs more than pharmacokinetics. Know the toxicity patterns, therapeutic ranges, drug interactions, and patient teaching points.

AED nursing implications — drug-by-drug reference

Phenytoin toxicity progression — NCLEX priority

Phenytoin has a narrow therapeutic index and exhibits non-linear (zero-order) pharmacokinetics at therapeutic levels, meaning small dose increases can cause disproportionately large rises in serum concentration. Toxicity follows a predictable, dose-related progression that NCLEX tests directly:

Stage 1 — Nystagmus (levels above ~20 mcg/mL) The earliest and most reliable sign of phenytoin toxicity. Sustained horizontal nystagmus at lateral gaze appears before any other neurological finding. If a patient on phenytoin develops new-onset nystagmus, draw a serum level immediately.

Stage 2 — Ataxia (levels above ~30 mcg/mL) Cerebellar toxicity causes gait instability and coordination problems. Patients may stumble or appear intoxicated. Fall precautions become mandatory.

Stage 3 — Mental status changes (levels above ~40 mcg/mL) Confusion, sedation, and cognitive impairment. The patient may be disoriented or difficult to rouse.

Stage 4 — Cardiac toxicity (IV administration, toxic serum levels) Severe cardiac effects include hypotension, bradycardia, heart block, and fatal ventricular arrhythmias. These are primarily risks with IV phenytoin administered too rapidly. The maximum safe IV rate is 50 mg/minute; in elderly patients and those with cardiac disease, administer at 25 mg/min or less with continuous cardiac monitoring.

Nursing rule: The toxicity mnemonic is N-A-C: Nystagmus → Ataxia → Confusion → Cardiac. Each stage represents an escalating emergency requiring provider notification and likely dose reduction or hold.

Additional AED nursing considerations

Therapeutic drug monitoring: Most AEDs require periodic serum level monitoring to keep drug concentrations within the therapeutic window. Levels drawn too soon after a dose change do not reflect steady state. Draw trough levels (just before the next dose) for accurate baseline assessment.

Enzyme-inducing AEDs: Carbamazepine, phenytoin, and phenobarbital induce hepatic cytochrome P450 enzymes, accelerating the metabolism of many other drugs — including hormonal contraceptives, warfarin, and some antibiotics. Women of childbearing age taking enzyme-inducing AEDs must be counseled that oral contraceptives may fail.

Abrupt discontinuation: Never stop AEDs abruptly in a patient with an active seizure disorder. Sudden withdrawal triggers rebound seizure activity that can progress to status epilepticus. Any planned discontinuation must be supervised with a gradual taper.

Patient teaching — what to tell all AED patients:

• Take doses at the same time each day
• Never stop the medication without provider guidance — even if feeling well
• Report any new rash immediately (SJS risk with several AEDs)
• Avoid alcohol and CNS depressants
• Phenytoin: good oral hygiene and regular dental visits reduce gingival hyperplasia
• Carbamazepine and valproate: avoid during pregnancy; discuss with provider before conceiving

Anti-Parkinson’s medications

Parkinson’s disease is characterized by the progressive loss of dopaminergic neurons in the substantia nigra, leading to the classic triad of tremor, rigidity, and bradykinesia. Pharmacological management aims to restore dopamine signaling in the basal ganglia through several complementary strategies: replacing dopamine (levodopa), stimulating dopamine receptors directly (dopamine agonists), preventing dopamine breakdown (MAO-B inhibitors, COMT inhibitors), or blocking the relative excess of acetylcholine that occurs when dopamine is depleted (anticholinergics). For clinical context on Parkinson’s disease assessment and nursing care, see the Parkinson’s disease nursing guide.

Levodopa/carbidopa (Sinemet)

Levodopa is the gold standard of Parkinson’s pharmacotherapy and the most effective drug available for motor symptom control. It works by crossing the blood-brain barrier and converting to dopamine in the surviving nigral neurons and striatum, directly replenishing the depleted neurotransmitter.

Why carbidopa is always combined with levodopa: Levodopa administered alone is converted to dopamine in the peripheral tissues before it can cross the blood-brain barrier, causing nausea, vomiting, and cardiovascular side effects while reducing CNS efficacy. Carbidopa inhibits peripheral dopa decarboxylase — the enzyme that converts levodopa to dopamine in peripheral tissues — without crossing the blood-brain barrier itself. The combination allows 75–80% lower doses of levodopa to achieve the same therapeutic effect with far fewer peripheral side effects.

Critical nursing considerations:

Timing is everything. Levodopa/carbidopa must be given at consistent, scheduled intervals. Even a 15–30 minute delay in dosing can cause abrupt return of Parkinsonian symptoms. In hospitalized patients, nurses must know to give this medication on schedule — never “hold for now” without anticipating motor deterioration.

Protein interactions. Large neutral amino acids in high-protein foods compete with levodopa for absorption at the gut wall and blood-brain barrier transport. High-protein meals can blunt the therapeutic effect. Standard guidance: take the medication 30–60 minutes before meals or 2 hours after; distribute protein intake evenly throughout the day rather than in one large meal.

Food and orthostatic hypotension. Levodopa causes orthostatic hypotension — a significant fall risk. Teach patients to rise slowly, dangle legs before standing, and increase fluid intake. Monitor blood pressure in lying and standing positions.

The “on-off” phenomenon — NCLEX high yield

After several years of levodopa therapy, patients often develop motor fluctuations — predictable and unpredictable alternation between periods of adequate symptom control (“on” state) and periods of breakthrough rigidity and tremor (“off” state).

Wearing-off (also called end-of-dose deterioration) is the most common motor fluctuation. The therapeutic effect of each levodopa dose diminishes before the next dose is due — patients experience the return of tremor, rigidity, or bradykinesia in the hour or two before their next scheduled dose. Management strategies include shortening dosing intervals, adding a COMT inhibitor (entacapone), or switching to extended-release formulations.

On-off fluctuations are more unpredictable — the patient switches rapidly between mobile “on” periods and frozen “off” periods without clear relationship to dosing timing. Management often requires adjunctive therapy or advanced interventions (subcutaneous apomorphine, deep brain stimulation).

NCLEX pearl: A patient on long-term levodopa reports episodes of inability to move despite taking medications as prescribed. This is the “off” phenomenon — a complication of long-term levodopa therapy, not medication non-compliance or disease progression alone.

Dyskinesias are involuntary, writhing or choreiform movements that occur during “on” periods when dopamine levels are at their peak. They represent over-medication relative to the available receptor density, not toxicity in the traditional sense. Patients sometimes prefer mild dyskinesias to being “off” — this is a clinical management decision made with the patient and their neurologist.

Dopamine agonists — pramipexole and ropinirole

Dopamine agonists stimulate dopamine receptors directly without requiring conversion. They can be used as monotherapy in early Parkinson’s to delay levodopa initiation (and thus delay the onset of motor fluctuations), or as adjuncts in later stages.

Key side effects:

• Nausea, dizziness, and orthostatic hypotension — common on initiation; dose titrated slowly
• Somnolence and sudden sleep attacks — patients should not drive until tolerability is established; warn about this explicitly
• Hallucinations and psychosis — more common in elderly patients; can cause significant confusion requiring dose reduction
• Impulse control disorders (ICDs) — This is a frequently tested NCLEX topic. Dopamine agonists are associated with pathological gambling, hypersexuality, compulsive shopping, and binge eating. Patients and caregivers should be counseled about these behaviors before starting treatment; many patients do not recognize the connection between the medication and the behavior. If a patient or family member reports new compulsive behaviors in a Parkinson’s patient, ask about dopamine agonist use.

MAO-B inhibitors — selegiline and rasagiline

MAO-B (monoamine oxidase B) is the primary enzyme responsible for breaking down dopamine in the brain. Inhibiting MAO-B raises synaptic dopamine levels and extends the duration of levodopa effect.

Key nursing considerations:

• Selegiline metabolizes to amphetamine — patients may experience insomnia; give doses early in the day
• Serious interaction risk with meperidine (Demerol) — can cause serotonin syndrome with hyperthermia, rigidity, and death; this combination is absolutely contraindicated; meperidine is also problematic with other MAOIs
• Relatively less dietary tyramine restriction needed compared to non-selective MAOIs (MAO-A inhibitors), but high-tyramine foods (aged cheeses, cured meats, fermented products) should still be limited
• Rasagiline is generally preferred over selegiline due to cleaner pharmacokinetics and no amphetamine metabolite

COMT inhibitors — entacapone

Catechol-O-methyltransferase (COMT) degrades levodopa in peripheral tissues. Entacapone inhibits COMT, extending the half-life of levodopa and smoothing out wearing-off.

• Always given with each levodopa dose — it has no effect when given alone
• Causes orange or brown discoloration of urine — teach patients this is expected and harmless
• GI side effects (diarrhea, nausea) are common
• Can worsen dyskinesias if levodopa dose is not adjusted

MS disease-modifying therapies

Multiple sclerosis is an autoimmune demyelinating disease in which the immune system attacks myelin sheaths in the central nervous system, causing recurring episodes of neurological dysfunction (relapses) with variable recovery. Disease-modifying therapies (DMTs) do not reverse damage already done — they reduce the frequency and severity of relapses and slow accumulation of disability. For comprehensive assessment and clinical nursing management, see the multiple sclerosis nursing reference.

Nurses encounter DMTs primarily in outpatient neurology, infusion center, and home health settings. The key nursing roles are: supporting safe administration, monitoring for adverse effects, and teaching patients about what to report.

Interferon beta (Avonex, Rebif, Betaseron, Plegridy)

Interferon beta preparations modulate the immune response — they reduce T-cell activation, decrease production of inflammatory cytokines, and stabilize the blood-brain barrier. They are administered by subcutaneous or intramuscular injection on regular schedules (weekly to every two weeks depending on formulation).

Nursing focus:

• Injection site reactions — redness, pain, lipoatrophy at injection sites. Teach patients to rotate sites systematically and inspect each site. Necrosis can occur if injection technique is poor.
• Flu-like syndrome — fever, chills, myalgia, and fatigue are common after each injection, especially early in therapy. Usually managed with pre-medication using ibuprofen or acetaminophen and administration on evenings before rest days. Symptoms typically improve after the first few months.
• Liver function monitoring — interferons can cause transaminase elevations; LFTs are checked at baseline and periodically
• Depression — interferon beta is associated with worsening depression; assess mental health regularly; this is a contraindication in severe depression

Glatiramer acetate (Copaxone, Glatopa)

Glatiramer acetate is a synthetic polypeptide that resembles myelin basic protein and appears to act as a “decoy” — diverting immune attack away from myelin. It is administered by daily or three-times-weekly subcutaneous injection.

Nursing focus:

• Injection site reactions are common — rotate sites, use room-temperature medication (cold injections cause more pain)
• Immediate post-injection reaction (IPIR): Up to 15% of patients experience a benign, self-limiting reaction within minutes of injection — chest tightness, flushing, palpitations, dyspnea, anxiety. This is not an allergic reaction and resolves within 30 minutes. Patients must be educated about IPIR before the first injection to prevent panic and unnecessary emergency visits.
• No significant drug interactions; no required lab monitoring beyond baseline

Natalizumab (Tysabri)

Natalizumab is a monoclonal antibody that blocks alpha-4 integrin, preventing immune cells from crossing the blood-brain barrier into the CNS. It is one of the most effective agents for relapsing MS but carries a serious risk that requires dedicated nursing attention.

Progressive multifocal leukoencephalopathy (PML): PML is a life-threatening opportunistic brain infection caused by reactivation of the JC virus (John Cunningham virus) — a common, usually dormant virus — in immunosuppressed patients. Natalizumab significantly increases PML risk, particularly after 24 months of treatment and in JC virus antibody-positive patients with prior immunosuppressant use.

Nursing implications:

• JC virus antibody testing is performed at baseline and every 6 months; antibody-positive status plus prolonged treatment markedly increases PML risk
• Natalizumab is available only through a restricted program (TOUCH prescribing program — REMS)
• Infusions are given IV every 4 weeks in monitored infusion centers
• Monitor for new or worsening neurological symptoms — cognitive changes, weakness, vision changes, speech problems — these could indicate PML and require immediate MRI evaluation
• Infusion reactions: chills, fever, nausea, urticaria — have emergency resuscitation equipment available

Ocrelizumab (Ocrevus)

Ocrelizumab is an anti-CD20 monoclonal antibody that depletes B lymphocytes, reducing the inflammatory activity driving MS. It is the only FDA-approved agent for primary progressive MS in addition to relapsing forms.

Nursing focus:

• IV infusion every 6 months; slower initial infusion rate with monitoring for infusion reactions
• Pre-medicate with corticosteroids, antihistamine, and antipyretic before each infusion
• Hepatitis B reactivation risk — screen all patients before starting; do not administer to patients with active hepatitis B infection
• Increased infection risk — patients should have updated vaccinations before starting (live vaccines contraindicated once on therapy)
• Monitor for infusion-related reactions (IRR) during and for one hour after infusion

Alzheimer’s and dementia medications

There are two pharmacological classes approved for Alzheimer’s disease symptom management: cholinesterase inhibitors and the NMDA receptor antagonist memantine. These drugs do not cure or reverse Alzheimer’s disease, and patients and families must understand this clearly before treatment begins. The goal of therapy is to slow the rate of cognitive decline and maintain functional ability longer — not to restore lost function.

For comprehensive nursing assessment and care of Alzheimer’s patients, see the Alzheimer’s disease nursing guide.

Cholinesterase inhibitors — donepezil, rivastigmine, galantamine

In Alzheimer’s disease, cholinergic neurons in the basal forebrain degenerate progressively, reducing acetylcholine (ACh) availability in the hippocampus and cerebral cortex — brain regions critical for memory and cognition. Cholinesterase inhibitors block acetylcholinesterase, the enzyme that breaks down ACh in the synaptic cleft, increasing the concentration and duration of action of whatever ACh remains.

Class-wide side effects — cholinergic excess: All cholinesterase inhibitors increase cholinergic tone throughout the body. This produces predictable side effects driven by the same mechanism that makes them therapeutically useful:

• GI effects — nausea, vomiting, diarrhea, and anorexia are the most common reasons for dose reduction or discontinuation. Start low and titrate slowly; giving with food reduces nausea. NCLEX question stem: “a patient started on donepezil reports nausea, vomiting, and decreased appetite” — this is an expected cholinergic side effect, managed by administration with food and dose titration, not automatic discontinuation.
• Bradycardia — ACh slows the sinoatrial node; monitor pulse before administration, especially in patients with pre-existing conduction disease or those on beta-blockers or digoxin
• Increased gastric acid secretion — increases peptic ulcer risk; use with caution in patients with a history of GI ulcers or who take NSAIDs regularly
• Bronchoconstriction — can worsen asthma or COPD; assess respiratory status
• Urinary urgency and frequency — related to increased detrusor tone; assess for urinary incontinence

What to tell families: Cholinesterase inhibitors slow the progression of symptoms — they do not reverse damage or restore lost memory. Early improvements in attention or daily function are possible but variable. The goal is maintaining function, not recovery.

Memantine (Namenda) — NMDA antagonist

Memantine has a completely different mechanism from cholinesterase inhibitors. In Alzheimer’s disease, excessive glutamate activity leads to sustained activation of NMDA (N-methyl-D-aspartate) receptors, triggering calcium influx and neuronal excitotoxicity — contributing to ongoing neuronal death. Memantine is a low-affinity, uncompetitive NMDA receptor antagonist that blocks this pathological glutamate signaling without entirely preventing normal synaptic transmission.

Approved use: Moderate-to-severe Alzheimer’s disease. It is often used in combination with a cholinesterase inhibitor in moderate-to-severe disease — a combination product (donepezil + memantine, brand name Namzaric) is available.

Key nursing considerations:

• Side effect profile is milder than cholinesterase inhibitors — dizziness, headache, and confusion are the most common; serious adverse effects are rare
• Dose titration: start at 5 mg daily and increase by 5 mg increments at weekly intervals to target dose of 20 mg/day
• Renal dosing: memantine is renally cleared; reduce dose in patients with significant renal impairment (CrCl below 30 mL/min)
• No food interactions; can be taken with or without food
• NCLEX distinction: Memantine is an NMDA antagonist; cholinesterase inhibitors are AChE inhibitors. They work through entirely different mechanisms and address different aspects of Alzheimer’s pathophysiology. The NCLEX may ask which class works on glutamate (memantine) versus acetylcholine (cholinesterase inhibitors).

NCLEX high-yield summary

The following tables condense the most testable nursing implications across all neurological drug categories.

For additional context on altered neurological states and assessment priorities, review the Glasgow Coma Scale nursing guide, the stroke nursing reference, and the ICP nursing guide.

Related references

• Seizure nursing reference — classification, assessment, and status epilepticus protocol
• Parkinson’s disease nursing guide
• Alzheimer’s disease nursing guide
• Multiple sclerosis nursing reference
• Psychiatric medications nursing reference
• Cardiovascular medications nursing reference
• Stroke nursing reference
• Glasgow Coma Scale nursing guide
• ICP nursing reference